New hope for cancer patients who stopped responding to immunotherapy?

NCT ID NCT07219576

Recruiting now Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether combining two drugs—retifanlimab and ruxolitinib—can safely help people with advanced lung or kidney cancer whose disease has progressed after prior immunotherapy. About 40 participants will take ruxolitinib pills twice daily and receive retifanlimab infusions every four weeks. The main goal is to find the safest dose of ruxolitinib to use with retifanlimab and to see if the combination shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: retifanlimab and ruxolitinib
What this could lead to: If it works, this could point toward a new treatment option for people with advanced lung or kidney cancer whose disease has worsened after immunotherapy.
What could go wrong: This is an early-phase trial with only 40 participants, so the combination may not prove effective or safe enough for wider use. Side effects from the drugs could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma non-small cell lung carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CARCINOMA RENAL CELL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

University of California, San Diego Moores Cancer Center
RECRUITING

La Jolla, California, 92093, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.